Analysis of AKT1 p.E17K Mutation in Biliary Tract and Liver Carcinomas
Author Information
Author(s): Riener M-O, Bawohl M, Clavien P-A, Jochum W
Primary Institution: University Hospital Zurich
Hypothesis
The AKT1 p.E17K mutation may be present in carcinomas of the biliary tract and liver.
Conclusion
The study found no AKT1 p.E17K mutations in any of the 118 carcinomas of the biliary tract and liver examined.
Supporting Evidence
- The study did not find the AKT1 p.E17K mutation in any of the 118 carcinomas examined.
- The findings suggest that cholangiocarcinoma and gallbladder carcinoma lack the AKT1 p.E17K mutation.
Takeaway
The researchers looked for a specific mutation in liver and bile duct cancers but didn't find it in any of the samples they tested.
Methodology
The study used polymerase chain reaction (PCR) and direct DNA sequencing to analyze tumor tissues for mutations.
Limitations
The study only examined a specific set of carcinomas and did not explore other potential mutations.
Participant Demographics
The study included 118 carcinomas from the biliary tract and liver, including various types of cholangiocarcinomas and hepatocellular carcinomas.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website